Lotus Pharmaceutical September Revenue Rises to NT$2.77 Billion
Lotus Pharmaceutical reported September and January-September 2026 revenue alongside figures for the corresponding periods of 2025.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to Dow Jones Newswires, Lotus Pharmaceutical Co. Ltd. generated revenue of NT$2,766,433,000 in September 2026, compared with NT$1,213,533,000 a year earlier. The figures are reported in New Taiwan dollars.
Revenue for January-September 2026 totaled NT$24,818,419,000, versus NT$14,247,508,000 in the corresponding period of 2025. The Taiwan Stock Exchange was listed as the data source.
why it matters
The release provides comparable revenue figures for Lotus Pharmaceutical across September and the first nine months of 2026 and 2025, allowing the market to assess the company’s sales scale on a year-on-year basis.
instruments
sources
- Table: Lotus Pharmaceutical Sep Rev NT$2.77B Vs NT$1.21B — Dow Jones Newswires, 12 October 2026 at 09:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗